Abstract
Obestatin is described as an anorexigenic peptide, and has adverse effects of ghrelin. It has no inhibitory effects on acute/chronic food intake, and it has been reported by several researchers. The role of obestatin in metabolism is still not clear. In the present study, the purpose is to determine the effects of chronically administrated obestatin. For this purpose, (1 µmol/kg; i.p.) or ghrelin (1 mol/kg; i.p.) and food restriction (24h fast:24h fed) on plasma obestatin, ghrelin, leptin, insulin, cholecystokinin (CCK) and glucose levels, and body weight gain were investigated for 14 days in mice. Additionally, mice were treated with acute ip (100 nmol/kg) injections of obestatin or ghrelin to investigate the food consumptions, plasma obestatin and ghrelin levels to determine unknown acute effects of obestatin. Plasma ghrelin levels increased significantly in obestatin administered mice when compared with the control group for chronic treatment. This increase is consistent with immunohistochemical findings which claim that the number of ghrelin and obestatin immunopositive cells in fundus tissue of stomach are considerably high in obestatin treated animals. Plasma obestatin and ghrelin levels has shown an increase endogenously in food restricted mice, but plasma leptin and insulin levels have been found to be lower compared to the control group. Acute administration of obestatin caused a decrease in plasma obestatin level at 60 min after injection and had no effect on the reduction of food intake in each treatment time. These results imply that obestatin may not itself be involved in the metabolism regulation; however, obestatin accompanied by ghrelin may play a role in the long-term regulation of metabolism.
Keywords: Acute effects, Chronic effects, Ghrelin, Metabolic regulating hormones, Obestatin.
Graphical Abstract
Protein & Peptide Letters
Title:Obestatin and Ghrelin May Have a Complementary Function During Acute and Chronic Period in Mice
Volume: 23 Issue: 4
Author(s): Duygu Udum, Deniz Belenli, Tuncay Ilhan, Nazmiye Gunes, Fusun Sonat and Murat Yalcin
Affiliation:
Keywords: Acute effects, Chronic effects, Ghrelin, Metabolic regulating hormones, Obestatin.
Abstract: Obestatin is described as an anorexigenic peptide, and has adverse effects of ghrelin. It has no inhibitory effects on acute/chronic food intake, and it has been reported by several researchers. The role of obestatin in metabolism is still not clear. In the present study, the purpose is to determine the effects of chronically administrated obestatin. For this purpose, (1 µmol/kg; i.p.) or ghrelin (1 mol/kg; i.p.) and food restriction (24h fast:24h fed) on plasma obestatin, ghrelin, leptin, insulin, cholecystokinin (CCK) and glucose levels, and body weight gain were investigated for 14 days in mice. Additionally, mice were treated with acute ip (100 nmol/kg) injections of obestatin or ghrelin to investigate the food consumptions, plasma obestatin and ghrelin levels to determine unknown acute effects of obestatin. Plasma ghrelin levels increased significantly in obestatin administered mice when compared with the control group for chronic treatment. This increase is consistent with immunohistochemical findings which claim that the number of ghrelin and obestatin immunopositive cells in fundus tissue of stomach are considerably high in obestatin treated animals. Plasma obestatin and ghrelin levels has shown an increase endogenously in food restricted mice, but plasma leptin and insulin levels have been found to be lower compared to the control group. Acute administration of obestatin caused a decrease in plasma obestatin level at 60 min after injection and had no effect on the reduction of food intake in each treatment time. These results imply that obestatin may not itself be involved in the metabolism regulation; however, obestatin accompanied by ghrelin may play a role in the long-term regulation of metabolism.
Export Options
About this article
Cite this article as:
Udum Duygu, Belenli Deniz, Ilhan Tuncay, Gunes Nazmiye, Sonat Fusun and Yalcin Murat, Obestatin and Ghrelin May Have a Complementary Function During Acute and Chronic Period in Mice, Protein & Peptide Letters 2016; 23 (4) . https://dx.doi.org/10.2174/0929866523666160204123526
DOI https://dx.doi.org/10.2174/0929866523666160204123526 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Characterization of Carboxymethyl Chitosan Hydrogel: Application as pH-Sensitive Delivery for Nateglinide
Current Drug Delivery Metabolic Signaling to the Central Nervous System: Routes Across the Blood Brain Barrier
Current Pharmaceutical Design mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery Locomotor Training and Factors Associated with Blood Glucose Regulation After Spinal Cord Injury
Current Pharmaceutical Design Prevalence of Diabetes Among Immigrants in the Nordic Countries
Current Diabetes Reviews Small Molecules as SIRT Modulators
Mini-Reviews in Medicinal Chemistry Atherosclerotic Process in Seroreverter Children and Adolescents Exposed to Fetal Antiretroviral Therapy
Current HIV Research Animal Models for Growth Hormone Gene Therapy
Current Gene Therapy Vildagliptin Induces β-Cell Neogenesis and Improves the Lipid Profile in a Later Phase of Type 1 Diabetes
Current Pharmaceutical Biotechnology Homo obesus: A Metabotrophin-Deficient Species. Pharmacology and Nutrition Insight
Current Pharmaceutical Design Alpha-Secretase As a Therapeutic Target
Current Alzheimer Research Neuroprotective Effects of Lithium - Pointing out Protein Phosphatases as Drug Targets?
Current Medicinal Chemistry - Central Nervous System Agents subject Index To Volume 3
Current Protein & Peptide Science Proposing a “Lipemic Index” As a Nutritional and Research Tool
Current Vascular Pharmacology Redox Mechanisms of Vascular Cell Dysfunction in Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Advanced Glycation and Advanced Lipoxidation: Possible Role in Initiation and Progression of Diabetic Retinopathy
Current Pharmaceutical Design Renal Function Impairment in Patients Undergoing Elective EVAR vs. Elective Open Repair During Follow up Period: A Systematic Review of the Literature
Current Vascular Pharmacology Involvement of the Septo-Hippocampal Cholinergic Pathway in Association with Septal Acetylcholinesterase Upregulation in a Mouse Model of Tauopathy
Current Alzheimer Research